Polycystic Ovary Syndrome is a common endocrine predisposition that affects 15 to 25%(1) of women of childbearing age and is the leading cause of infertility(2).
In 60 to 70% of cases, metabolic disorders associated with insulin resistance are noted(3).
The clinical implications of PCOS are multiple(4):
- Menstrual cycle disorders (long cycle, absence of ovulation, etc.)
- Decreased fertility
- Too high production of male hormones (androgens) causing acne, hirsutism
- Metabolic complications (overweight, arterial hypertension, dyslipidemia, etc.)
Women with PCOS also have nutrient deficiencies (vitamin D(5), folate / vitamin B9(6), chromium(7), zinc(8), etc.) directly or indirectly related to the condition or its symptoms(9).
Zytolia® is a product based on Myo-inositol (4g), Vitamins (B9 400µg, D3 5µg) and Minerals (zinc 10mg, chromium 25µg) specially formulated for the nutritional needs of women with polycystic ovary syndrome (PCOS).
Zytolia® is intended for all women with PCOS with hyperandrogenism and / or insulin resistance and / or overweight or obesity:
– as part or not of a pregnancy project,
– in case of contraindication to estrogen-progestogen hormonal contraception or reluctance to take the hormone,
– in addition to inducing ovulation treatment or an IVF protocol,
– in the event of pregnancy with insulin resistance.
- Myo-inositol works by reducing insulin resistance, hyperinsulinism, hyperandrogenism and improving fertility (oocyte quality, follicular growth and ovulation).(10, 11, 12, 13)
– Vitamin B9 helps to reduce the levels of homocysteines (an essential amino acid required for cell and tissue growth) found to be too high in women with PCOS and often associated with complications of PCOS(14).
– Vitamin D3, by reducing insulin resistance improves sensitivity(15).
- The minerals:
– Chromium increases insulin sensitivity and facilitates the transport of glucose into cells(16).
– Zinc plays a role in the metabolism of insulin and is thought to act on its resistance and on hyperinsulinism(17).
Stick with “easy-open” opening
Take 2 sticks per day, morning and evening for a better absorption, diluted in a glass of water (150ml) for at least 3 months.
Box of 60 powder sticks for oral solution, 1-month cure, EAN code: 3 700 111 400 269
1. Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med. 2014;127(10):912–919. doi:10.1016/j.amjmed.2014.04.017.
2. Merviel P et al. Quelles stimulations pour quelles femmes : le syndrome des ovaires polykystiques. Gynecol Obstet Fertil Senol. 2017 Nov ; 45(11) : 623-631.
3. Rolland AL, Dewailly D. Interet du myo-inositol dans le syndrome des ovaires polykystiques. Medecine de la Reproduction, Gynecologie, Endocrinologie 2015 ; 17(3)
4. Soni A, Singla S, Goyal S. Polycystic ovary syndrome: Pathogenesis, treatment and secondary associated diseases. Journal of Drug Delivery and Therapeutics. 2018; 8(5):107-112.
5. He C, Lin Z, Robb SW, Ezeamama AE (2015) Serum vitamin D levels and polycystic ovary syndrome: a systematic review and meta analysis. Nutrients 7:4555–4577. https ://doi.org/10.3390/nu706 4555
6. Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687–708. doi:10.1093/humupd/dmw025
7. Chakraborty P, Ghosh S, Goswami SK, Kabir SN, Chakravarty B, Jana K. Altered Trace Mineral Milieu Might Play An Aetiological Role in the Pathogenesis of Polycystic Ovary Syndrome. Biol Trace Elem Res 2013; 152: 9-15
8. Abedini, Maryam & Ghaedi, Ehsan & Hadi, Amir & Mohammadi, Hamed & Amani, Reza. (2019). Zinc Status and Polycystic Ovarian Syndrome: A systematic review and meta-analysis. Journal of Trace Elements in Medicine and Biology. 52. 10.1016/j.jtemb.2019.01.002
9. Gunalan E, Yaba A, Yılmaz B. The effect of nutrient supplementation in the management of polycystic ovary syndrome-associated metabolic dysfunctions: A critical review. J Turk Ger Gynecol Assoc. 2018;19(4):220– 232. doi:10.4274/jtgga.2018.0077
10. Huang LC, Fonteles MC, Houston DB, Zhang C, Larner J. Chiroinositol deficiency and insulin ressitance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology. 1993 Feb;132(2):652-7
11. Chiu TT, Rogers MS, Law EL, Jun;17(6):1591-6.
12. Ciotta L, Straquandacionio M, Pagano I, Carbonaro A, Palumbo M, Gulino F. Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients; a double blind trial. Eur Rev Med Pharmacol Sci. 2011 May;15(5):509-14.
13. Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013;29:375–9.
14. Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B, et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 2005; 20: 894-9
15. Łagowska, K., Bajerska, J., & Jamka, M. (2018). The Role of Vitamin D Oral Supplementation in Insulin Resistance in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 10(11), 1637.
16. Davis CM, Sumrall KH, Vincent JB. A biologically active form of chromium may activate a membrane phosphotyrosine phosphatase (PTP). Biochemistry, 1996; 35: 12963-12969
17. Chausmer AB. Zinc, insulin and diabetes. J Am Coll Nutr 1998; 17: 109-15